BACKGROUND: Multiple studies have demonstrated that a significant amount of variability exists in various demineralized bone matrix (DBM) formulations, which casts doubts on its reliability in consistently promoting fusion. Bone marrow aspirate (BMA) is a cellular based graft that contains mesenchymal stem cells (MSCs) and growth factors can confer osteogenic and osteoinductive potential to DBM. The goal of this study was to describe the outcome of DBM enriched with concentrated BMA in patients undergoing combined lumbar interbody and posterolateral fusion. METHODS: Eighty patients with a minimum of 12 months of follow-up were evaluated. Fusion and rates of complication were evaluated. Functional outcomes were assessed based on the modified Odom's criteria. Multiple logistic regression analysis was used to examine the effects of independent variables on fusion outcome. RESULTS: The overall rate of solid fusion (i.e patients with both solid posterolateral and interbody fusion) was 81.3% (65/80). Specifically, the radiographic evidence of solid posterolateral and interbody fusions were 81.3% (65/80) and 92.5% (74/80), respectively. Seven (8.75%) patients developed hardware-related complications, 2 (2.5%) patients developed a postoperative infection and 2 (2.5%) patients developed clinical pseudarthrosis. Charlson comorbidity index (CCI) scores of 3 and 4 were associated with non-solid unions (CCI-3, p = 0.048; CCI-4, p = 0.03). Excellent or good outcomes were achieved in 58 (72.5%) patients. CONCLUSIONS: Patients undergoing lumbar fusion using an enriched bone graft containing concentrated BMA added to DBM can achieve successful fusion with relatively low complications and good functional outcomes. Despite these findings, more studies with higher level of evidence are needed to better understand the efficacy of this promising graft option.
BACKGROUND: Multiple studies have demonstrated that a significant amount of variability exists in various demineralized bone matrix (DBM) formulations, which casts doubts on its reliability in consistently promoting fusion. Bone marrow aspirate (BMA) is a cellular based graft that contains mesenchymal stem cells (MSCs) and growth factors can confer osteogenic and osteoinductive potential to DBM. The goal of this study was to describe the outcome of DBM enriched with concentrated BMA in patients undergoing combined lumbar interbody and posterolateral fusion. METHODS: Eighty patients with a minimum of 12 months of follow-up were evaluated. Fusion and rates of complication were evaluated. Functional outcomes were assessed based on the modified Odom's criteria. Multiple logistic regression analysis was used to examine the effects of independent variables on fusion outcome. RESULTS: The overall rate of solid fusion (i.e patients with both solid posterolateral and interbody fusion) was 81.3% (65/80). Specifically, the radiographic evidence of solid posterolateral and interbody fusions were 81.3% (65/80) and 92.5% (74/80), respectively. Seven (8.75%) patients developed hardware-related complications, 2 (2.5%) patients developed a postoperative infection and 2 (2.5%) patients developed clinical pseudarthrosis. Charlson comorbidity index (CCI) scores of 3 and 4 were associated with non-solid unions (CCI-3, p = 0.048; CCI-4, p = 0.03). Excellent or good outcomes were achieved in 58 (72.5%) patients. CONCLUSIONS:Patients undergoing lumbar fusion using an enriched bone graft containing concentrated BMA added to DBM can achieve successful fusion with relatively low complications and good functional outcomes. Despite these findings, more studies with higher level of evidence are needed to better understand the efficacy of this promising graft option.
Entities:
Keywords:
bone marrow aspirate; demineralized bone matrix; lumbar fusion
Authors: George F Muschler; Hironori Nitto; Yoichi Matsukura; Cynthia Boehm; Antonio Valdevit; Helen Kambic; William Davros; Kimerly Powell; Kirk Easley Journal: Clin Orthop Relat Res Date: 2003-02 Impact factor: 4.176
Authors: George F Muschler; Yoichi Matsukura; Hironori Nitto; Cynthia A Boehm; Antonio D Valdevit; Helen E Kambic; William J Davros; Kirk A Easley; Kimerly A Powell Journal: Clin Orthop Relat Res Date: 2005-03 Impact factor: 4.176
Authors: Jeffrey C Wang; A Alanay; Davies Mark; Linda E A Kanim; Pat A Campbell; Edgar G Dawson; Jay R Lieberman Journal: Eur Spine J Date: 2007-01-05 Impact factor: 3.134
Authors: Rozalia Dimitriou; George I Mataliotakis; Antonios G Angoules; Nikolaos K Kanakaris; Peter V Giannoudis Journal: Injury Date: 2011-06-25 Impact factor: 2.586
Authors: Brett Peterson; Peter G Whang; Roberto Iglesias; Jeff C Wang; Jay R Lieberman Journal: J Bone Joint Surg Am Date: 2004-10 Impact factor: 5.284
Authors: Tucker C Callanan; Antonio T Brecevich; Craig D Steiner; Fred Xavier; Justin A Iorio; Celeste Abjornson; Frank P Cammisa Journal: Eur Spine J Date: 2018-12-03 Impact factor: 3.134
Authors: Joana M Ramis; Javier Calvo; Aina Matas; Cristina Corbillo; Antoni Gayà; Marta Monjo Journal: J Mater Sci Mater Med Date: 2018-06-28 Impact factor: 3.896
Authors: Simon Spalthoff; Rüdiger Zimmerer; Jan Dittmann; Horst Kokemüller; Marco Tiede; Laura Flohr; Philippe Korn; Nils-Claudius Gellrich; Philipp Jehn Journal: Regen Biomater Date: 2017-11-27